Generic Semaglutide to Cut Weight-Loss Drug Prices Dramatically Across Several Countries

Semaglutide, marketed as Ozempic and Wegovy, is losing patent protection in India, China, Turkey, and others, allowing generic versions to enter those markets. This shift could reduce monthly costs from hundreds of dollars to as low as $15, potentially expanding access for millions coping with obesity and diabetes. However, barriers remain, as patent laws in India may still limit affordable access despite the generic availability, raising concerns about equitable distribution.